Boosting an exercise-related gene in the brain works as a powerful anti-depressant ? a finding that could lead to a new antidepressant drug target.
– Boosting an exercise-related gene in the brain works as a powerful anti-depressant in mice – a finding that could lead to a new anti-depressant drug target, according to a Yale School of Medicine report in Nature Medicine.
Young women with past anorexia nervosa show vastly different patterns of brain activity compared to similar women without the eating disorder.
– Even after more than a year of maintaining a normalized body weight, young women who recovered from anorexia nervosa show vastly different patterns of brain activity compared to similar women without the eating disorder, Walter H. Kaye, M.D., professor of psychiatry, University of Pittsburgh School of Medicine, and colleagues report in the December issue of the American Journal of Psychiatry.
Sleep disordered breathing affects obese and overweight children. Obstructive sleep apnea (OSA) can pose serious health threats.
– As the obesity epidemic grows in the U.S., doctors are discovering more and more far reaching health concerns for overweight children. Sleep-disordered breathing (SDB), which can include various sleep behaviors ranging in severity from snoring to obstructive sleep apnea (OSA), disproportionately affects children who are overweight and African- American, according to a new study published in the December 2007 edition of Otolaryngology ? Head and Neck Surgery.
Obesity and being over-weight may be bad for bone health, and childhood obesity could have a significant, long lasting negative impact on the skeleton. – Obesity may be bad for bone health, revealed by researchers at the University of Georgia. Being overweight is a known risk factor for heart disease, diabetes and a host of other health conditions. Now, obesity and over-weight may also be bad for bone health.
Anticancer drug Nexavar raised survival period in inoperable hepatocellular carcinoma patients suffering from this kind of liver cancer. – The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma, a form of kidney cancer.
